Clinical trials: Human Leukocyte Antigens (HLA)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00253552
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Solid Tumor
Safety Study of Vx006 Vaccine in Solid Tumor Patients
Patients with histologically proven malignancy with documented disease control (objective response or stable disease) or Not Evaluable Disease (NED) expectancy > 6 months; only HLA-A*02 positive patients.
- Trial name
- NCT02289196
- Testing
- Vx-006: 0,5mg, Vx-006: 1mg, Vx-006: 5mg
- Where
- 3 sites in Greece
- Volunteers
- 23 people
- Sponsor
- Vaxon Biotech
Renal Insufficiency
Atorvastatin in the Recipient's Kidney Graft From a Living Donor
Renal insufficiency is a priority disease in the health system, which may require renal replacement therapy based on kidney transplantation, which is considered as therapy of choice.
- Trial name
- ATORV15 (NCT02522117)
- Testing
- Atorvastatin
- Where
- Mexico
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Instituto Mexicano del Seguro Social
Leukemia, Chronic Myelogenous Leukemia
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
The goal of this clinical research study is to learn if giving a kind of immune cell called natural killer (NK) cells after chemotherapy will improve the response to a stem cell transplant in patients with CML.
- Trial name
- NCT01390402
- Testing
- Fludarabine, Busulfan, NK cell infusion:
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer Resectable
Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers.
- Trial name
- NCT05483257
- Testing
- Multigene panel for next-generation sequencing
- Where
- China
- Volunteers
- 226 people
- Sponsor
- BAIYONG SHEN
Liver Transplantation
Role of Human Leukocyte Antigen Matching in Liver Transplantation and Its Relation to Outcomes
The study aimed to assess HLA compatibility, HLA antibodies and cross matching in liver transplantation recipients and their relation to acute rejection, CMV infection, and recurrence of HCV.
- Trial name
- NCT03094728
- Testing
- HLA cross matching
- Volunteers
- 24 people
- Sponsor
- Ain Shams University
Hematologic Malignancy
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
The purpose of this research study is to examine the survival of patients undergoing partially matched hematopoietic stem cell transplant (HSCT) on a new type of treatment approach, which has been developed specifically for…
- Trial name
- NCT01341301
- Testing
- Total Body Irradiation, Donor Lymphocyte Infusion (DLI), Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Ependymoma
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas.
- Trial name
- NCT01795313
- Testing
- HLA-A2 restricted synthetic tumor antigen, Imiquimod, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- James Felker
Acute Myeloid Leukemia, in Relapse
Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
This is a retrospective and prospective non-interventional multicenter observational study. Neither diagnostic approaches nor experimental drugs/procedure will be applied and the samples will take place at the same time as the…
- Trial name
- GITMO-RELAPSE (NCT05124288)
- Testing
- Observations on Relapsed AML Allogeneic Transplanted patients
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Ciceri Fabio
Pancreatic Cancer, Pancreas Neoplasms
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer death in the United States, and no combination therapy is far superior to gemcitabine alone.
- Trial name
- NCT00683085
- Testing
- HLA-A*02:01-restricted VEGFR1-derived peptide vaccination
- Where
- Japan
- Volunteers
- 2 people
- Sponsor
- Tokyo University
Aplastic Anemia
Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia
Rationale: Chemotherapy with fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic cell transplantation.
- Trial name
- NCT01105273
- Testing
- anti-thymocyte globulin, filgrastim, Fludarabine
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Asan Medical Center
Highly Sensitized Prospective Kidney Transplant Recipients
Daratumumab and Belatacept for Desensitization
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors.
- Trial name
- ATTAIN (NCT04827979)
- Testing
- daratumumab, belatacept, Bone marrow aspiration
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Gastric Cancer
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer
The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent gastric cancer.
- Trial name
- NCT00845611
- Testing
- peptide vaccine
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Kinki University
Breast Cancer
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
The purpose of this research study is to evaluate Immunotherapy with a peptide vaccine and Programmed Death Ligand 1 (PD-L1) inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer.
- Trial name
- NCT02826434
- Testing
- PVX-410, Durvalumab, Hiltonol
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Adoptive Transfer of Haplo-identical DLI for AML and MDS
The primary hypothesis is that chemotherapy followed by donor lymphocyte infusion (DLI) from HLA-haploidentical donors is a safe procedure that will not cause Graft versus Host Disease (GVHD) or increased treatment-related…
- Trial name
- NCT02046122
- Testing
- Idarubicin, Cytarabine, DLI
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Duke University
Acute Leukemias, Burkitt's Lymphoma
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen.
- Conditions
- Acute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT02145039
- Testing
- Fludarabine, Cyclophosphamide, Total Body Irradiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Burns
The Relationship Between Cadaveric Allograft Skin and HLA-Sensitivity in Burn Patients
The purpose of this research study is to look at how the body's immune system reacts to temporary skin grafts from deceased donors.
- Trial name
- NCT04162639
- Testing
- Skin allograft
- Sponsor
- Virginia Commonwealth University
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just completed an 8 month trial of MMF treatment alone.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446251
- Testing
- Rituximab, Mycophenolate mofetil (MMF)
- Volunteers
- 14 people
- Sponsor
- University of Washington
Immunosuppression
Monitoring of Corticosteroids Induced Immunosuppression Using Monocyte Human Leukocyte Antigen-DR (mHLA-DR).
Corticotherapy is widely used in auto-immune diseases. If induced immunosuppression by corticosteroids is well admitted, it's currently not possible to determine individual risk of infection.
- Trial name
- HLA-DR (NCT04360772)
- Testing
- mHLA-DR
- Sponsor
- Hospices Civils de Lyon
Infertility
Maternal and Fetal Compatibility in Assisted Reproductive Technology (ART)-Oocyte Donor Influences Live Birth Rate
Has the maternal KIR haplotype an impact in pregnancy, miscarriage and live birth rates per embryo transfer in donor oocytes -ART by paternal and oocyte donor HLA-C?
- Trial name
- NCT02718105
- Testing
- KIR HLAC determinations
- Where
- Spain
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- IVI Madrid